OverviewChartNewsTraderScreen

UBS Call 240 BNTX 21.06.2024/  DE000UL07544  /

Frankfurt Zert./UBS
2024-05-31  7:37:43 PM Chg.-0.004 Bid9:53:37 PM Ask9:53:37 PM Underlying Strike price Expiration date Option type
0.038EUR -9.52% -
Bid Size: -		 -
Ask Size: -		 BioNTech SE 240.00 USD 2024-06-21 Call
GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire 05-28 Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 05-21 Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire 05-17 Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire 05-09 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
TeleTrader 05-06 BioNTech's Q1 revenue slumps 85% to €187.6M
GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
TeleTrader 05-06 Europe mixed premarket with data on the limelight
GlobeNewswire 05-02 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 04-10 Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first...
GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire 04-04 Medigene AG Secures European Patent for its iM-TCR Technology
GlobeNewswire 03-28 Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-27 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
TeleTrader 03-20 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
TeleTrader 03-20 Europe mixed premarket amid data
GlobeNewswire 03-14 Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GlobeNewswire 03-12 The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline – ...
GlobeNewswire 03-11 BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Co...
GlobeNewswire 03-11 FINAL DEADLINE REMINDER FOR BNTX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead ...